Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feinsilver, O.
Right arrow Articles by Aviado, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feinsilver, O.
Right arrow Articles by Aviado, D. M.
(Chest. 1970;58:558-561.)
© 1970 American College of Chest Physicians

Pharmacology of a New Antianginal Drug: Perhexiline

III. Bronchopulmonary System in the Dog and Humans

Oscar Feinsilver M.D., F.C.C.P.1; Young W. Cho M.D., F.C.C.P.1; and Domingo M. Aviado M.D.1

1 Medical Service, St. Vincent Hospital, Worcester, Massachusetts, the Department of Pharmacology, University of Pennsylvania, Philadelphia, and the Department of Medical Research, The William S. Merrell Company, Division of Richardson-Merrell, Inc., Cincinnati

Perhexiline elicited bronchodilatation in anesthetized dogs and asthmatic patients. In the latter, the effect was manifested by a fall in airway resistance. In some patients, an increase was observed in forced expiratory volume, lung volume, forced vital capacity and maximum expiratory flow rate respectively.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1970 by the American College of Chest Physicians.